Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04796922
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 654
- Registration Number
- NCT04680052
- Locations
- 🇺🇸
John Muir Health Clinical Research Center, Concord, California, United States
🇺🇸Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc), Saint Louis Park, Minnesota, United States
🇺🇸Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT04640025
- Locations
- 🇩🇪
University Hospital Mannheim, Mannheim, Germany
🇮🇹Azienda Policlinico Vittorio Emanuele, Catania, Italy
🇮🇹Aou San Giovanni Di Dio E Ruggi, Salerno, Italy
Study of INCB086550 in Select Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT04629339
- Locations
- 🇺🇦
Medical Clinic Innovacia Llc, Vyshhorod, Ukraine
🇧🇬Shatod Dr. Marko - Varna Ltd, Varna, Bulgaria
🇭🇺Semmelweis Egyetem, Budapest, Hungary
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 4
- Registration Number
- NCT04629508
- Locations
- 🇮🇹
Treviso Hospital, Treviso, Italy
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇮🇹Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan, Italy
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04586244
- Locations
- 🇮🇹
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, Italy
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇫🇷Institut Gustave Roussy, Villejuif Cedex, France
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 22
- Registration Number
- NCT04582539
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan, United States
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04580485
- Locations
- 🇧🇪
Cliniques Universitaires Ucl Saint-Luc, Brussels, Belgium
🇺🇸Cedars-Sinai Medical Center, West Hollywood, California, United States
🇺🇸University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 177
- Registration Number
- NCT04551053
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 252
- Registration Number
- NCT04551066
- Locations
- 🇺🇸
Kelsey Seybold Clinic, Houston, Texas, United States
🇧🇪A.Z. St.-Jan A.V., Brugge, Belgium
🇺🇸Oregon Health & Science University, Portland, Oregon, United States